Literature DB >> 23105879

Circulating thrombotic and haemostatic components in patients with coronary artery disease.

Kavita K Shalia1, V K Shah, M R Mashru, S L Soneji, J B Vasvani, S S Payannavar, A P Walvalkar, R A Mokal, S M Mithbawkar, K V Kudalkar, A Abraham, P K Thakur.   

Abstract

The study aimed to analyze the circulating levels of thrombotic and haemostatic components; tissue factor, tissue factor pathway inhibitor, tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with acute myocardial infarction at presentation (Group 1, n=49), unstable angina and Non-ST elevated MI after treatment (Group 2, n=22), stable angina (Group 3, n=18) and healthy individuals (Group 4, n=31). Significant finding was increase in tissue factor not only in Group 1 (2.0 fold, P=0.001), Group 2 (2.2 fold, P=0.015) but also in Group 3 (1.8 fold, P=0.018) as compared to controls. In Group 1 Plasminogen activator inhibitor-1 increased significantly (35.8%, P=0.02). Tissue factor pathway inhibitor and tissue plasminogen activator demonstrated increase in Group 1 of age<40 years while insignificant changes in elder patients. Increased thrombotic and decreased fibrinolytic conditions in acute myocardial infarction patients were observed. Increase TF in stable angina demonstrates procoagulant status in these patients as well.

Entities:  

Keywords:  Acute Myocardial Infarction; Non-ST elevated MI; Stable angina; Thrombotic and haemostatic components

Year:  2010        PMID: 23105879      PMCID: PMC3453008          DOI: 10.1007/s12291-010-0005-2

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  48 in total

1.  Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study.

Authors:  P E Morange; S Blankenberg; M C Alessi; C Bickel; H J Rupprecht; R Schnabel; E Lubos; T Münzel; D Peetz; V Nicaud; I Juhan-Vague; L Tiret
Journal:  J Thromb Haemost       Date:  2007-01-04       Impact factor: 5.824

2.  Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis.

Authors:  K Kaikita; M Takeya; H Ogawa; H Suefuji; H Yasue; K Takahashi
Journal:  J Pathol       Date:  1999-06       Impact factor: 7.996

3.  Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression.

Authors:  M Guha; M A O'Connell; R Pawlinski; A Hollis; P McGovern; S F Yan; D Stern; N Mackman
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

4.  Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity.

Authors:  N M Caplice; C S Mueske; L S Kleppe; R D Simari
Journal:  Circulation       Date:  1998-09-15       Impact factor: 29.690

5.  TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications.

Authors:  G Novo; N Caplice; R Tantillo; F Bonura; R Simari; S Novo
Journal:  Int Angiol       Date:  2005-12       Impact factor: 2.789

6.  Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque.

Authors:  Fei Chen; Per Eriksson; Göran K Hansson; Istvan Herzfeld; Magareta Klein; Lars-Olof Hansson; Guro Valen
Journal:  Int J Mol Med       Date:  2005-01       Impact factor: 4.101

7.  Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction.

Authors:  H M Hoffmeister; M Jur; M Ruf-Lehmann; U Helber; W Heller; L Seipel
Journal:  J Am Coll Cardiol       Date:  1998-03-01       Impact factor: 24.094

8.  Tissue factor pathway inhibitor, natural coagulation inhibitors and hemostatic activation markers in patients with acute coronary syndromes.

Authors:  Mansour M Al-Nozha; Abdel-Galil M Abdel-Gader; Mohammed R Arafah; Mohammed A Al-Maatouq; Maie S Al-Shahid; Saad S Al-Harthi; Nazeer B Khan; Moheeb A Abdullah
Journal:  Saudi Med J       Date:  2005-06       Impact factor: 1.484

9.  High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

Authors:  A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690

10.  Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome.

Authors:  M Malý; J Vojácek; V Hrabos; J Kvasnicka; P Salaj; V Durdil
Journal:  Physiol Res       Date:  2003       Impact factor: 1.881

View more
  2 in total

1.  Comparison Between Serum hsCRP and LDL Cholesterol for Search of a Better Predictor for Ischemic Heart Disease.

Authors:  Subinay Datta; Zahidul Iqbal; K R Prasad
Journal:  Indian J Clin Biochem       Date:  2011-01-19

2.  Circulating Thrombotic Risk Factors in Young Patients with Coronary Artery Disease Who Are on Statins and Anti-platelet Drugs.

Authors:  Reema George; Harikrishnan Sivadasanpillai; Narayani Jayakumari; Anugya Bhatt; Jissa V Thulaseedharan; Jaganmohan A Tharakan
Journal:  Indian J Clin Biochem       Date:  2015-12-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.